Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

TNBC

Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 4 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 4 Jun 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 3 Jun 2026
A-BRAVE: time-of-day immunotherapy administration in early-stage TNBC
1:58
A-BRAVE: time-of-day immunotherapy administration in early-stage TNBC
Shipra Gandhi • 3 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 3 Jun 2026
KEYNOTE-522: final analysis of pembrolizumab and chemotherapy in TNBC
4:12
KEYNOTE-522: final analysis of pembrolizumab and chemotherapy in TNBC
Peter Schmid • 3 Jun 2026
Addressing access barriers and guideline-concordant breast cancer care
1:07
Addressing access barriers and guideline-concordant breast cancer care
Inimfon Jackson • 30 Jan 2026
ECOG-ACRIN EA1131: post-NACT TILs and intrinsic subtype in residual TNBC
2:36
ECOG-ACRIN EA1131: post-NACT TILs and intrinsic subtype in residual TNBC
Sunil Badve • 29 Jan 2026
CompassHER2 pCR: baseline TILs & pCR after THP in HER2+ breast cancer
3:11
CompassHER2 pCR: baseline TILs & pCR after THP in HER2+ breast cancer
Sunil Badve • 29 Jan 2026
TROPION-Breast02: first-line datopotamab deruxtecan in metastatic TNBC
7:05
TROPION-Breast02: first-line datopotamab deruxtecan in metastatic TNBC
Sung-Bae Kim • 12 Jan 2026
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
2:28
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
Inimfon Jackson • 23 Dec 2025
How are ADC and ICI combinations redefining breast cancer treatment?
4:22
How are ADC and ICI combinations redefining breast cancer treatment?
Laurence Buisseret • 18 Dec 2025
Residual immune microenvironment predicts relapse risk in early TNBC
1:30
Residual immune microenvironment predicts relapse risk in early TNBC
Abhishek Garg • 12 Dec 2025
Metastatic breast cancer updates at ESMO 2025
2:37
Metastatic breast cancer updates at ESMO 2025
Janice Wing-Hang Tsang • 5 Nov 2025
ESMO 2025: breakthrough ADC trials in TNBC and HER2+ breast cancer
1:24
ESMO 2025: breakthrough ADC trials in TNBC and HER2+ breast cancer
Erika Hamilton • 17 Oct 2025
The future landscape of treatment intensification strategies for TNBC
0:39
The future landscape of treatment intensification strategies for TNBC
Christian Singer • 1 Jul 2025
The content of VJOncology is intended for healthcare professionals